Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review

作者：Diego Prost, Soledad Iseas, Michel Gatineau, Julie Adam, Stefano Cavalieri, Cristiana Bergamini, Lisa Licitra, Éric Raymond · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103722 · 被引用次数：11 · 研究领域：Salivary Gland Tumors Diagnosis and Treatment、Salivary Gland Disorders and Functions、Ear and Head Tumors

BACKGROUND: Salivary gland cancers are infrequent and pose a challenge owing to their histological diversity and varied clinical behavior, making the selection of optimal systemic treatments for advanced or recurrent stages difficult. This systematic review aims to assess overall survival outcomes and systemic treatment responses across four types of salivary cancers. METHODS: A PubMed and Google Scholar search identified studies involving initially advanced or relapsed cases undergoing systemic treatment. Studies with clear, individualized data on treatment responses and outcomes were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Of the 723 studies screened, 44 met our inclusion criteria. RESULTS: A total of 426 cases of recurrent/metastatic salivary gland cancer, mostly salivary duct carcinoma (SDC; n = 219) and adenoid cyst carcinoma (ACC; n = 167), were included. Histomolecular markers were heavily associated with histology, with HER2 overexpression and androgen receptor nuclear expression typically found in SDC and adenocarcinoma not otherwise specified cases and KIT overexpression only in ACC. The response rates were associated with specific receptor blockage, with trastuzumab plus chemotherapy, and bicalutamide being the most effective (overall response rate 80% and 42.8%, respectively). Moreover, the response to treatment positively influenced overall survival (responders 38 versus non-responders 18.7 medi...